INHIBITION OF PCSK9 AFFECTS SERUM LIPOPROTEIN FUNCTIONS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA

被引：0
|
作者：
Palumbo, M. [1 ]
Adorni, M. P. [2 ]
Zimetti, F. [1 ]
Pavanello, C. [3 ]
Giammanco, A. [4 ]
Cefalu, A. B. [4 ]
Noto, D. [4 ]
Piro, S. [5 ]
Di Pino, A. [5 ]
Averna, M. [4 ]
Calabresi, L. [3 ]
Bernini, F. [1 ]
Purrello, F. [5 ]
Scicali, R. [5 ]
机构：
[1] Univ Parma, Dept Food & Drug, Parma, Italy
[2] Univ Parma, Dept Med & Surg, Unit Neurosci, Parma, Italy
[3] Univ Milan, Pharmacol & Biomol Sci, Milan, Italy
[4] Univ Palermo, Dept Hlth Promot Mother & Child Care Internal Med, Palermo, Italy
[5] ARNAS GARIBALDI NESIMA, Dept Med, Catania, Italy
来源：
ATHEROSCLEROSIS | 2022年 / 355卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EP222
引用
收藏
页码：E157 / E157
页数：1
相关论文
共 50 条
  • [1] PCSK9 inhibition in the management of familial hypercholesterolemia
    Ogura, Masatsune
    JOURNAL OF CARDIOLOGY, 2018, 71 (1-2) : 1 - 7
  • [2] PCSK9 inhibition in patients with hypercholesterolemia
    Desai, Nihar R.
    Sabatine, Marc S.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2015, 25 (07) : 567 - 574
  • [3] How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana, Luis
    Plana, Nuria
    Perez-Calahorra, Sofia
    Ibarretxe, Daiana
    Lamiquiz-Moneo, Itziar
    Pedro-Botet, Juan
    Suarez-Tembra, Manuel
    Valdivielso, Pedro
    Ortega, Emilio
    Civeira, Fernando
    ATHEROSCLEROSIS, 2017, 262 : 107 - 112
  • [4] PCSK9 IN FAMILIAL HYPERCHOLESTEROLEMIA (FH)
    Lambert, G.
    Rye, K. -A.
    Burnett, J.
    Barter, P.
    Marais, D.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 31 - 31
  • [5] PCSK9 Inhibitors for Familial Hypercholesterolemia
    Lenahan, Christy M.
    Harringtoon, Deedra
    JNP-JOURNAL FOR NURSE PRACTITIONERS, 2016, 12 (08): : 577 - 578
  • [6] LIPOPROTEIN(A) IN FAMILIAL HYPERCHOLESTEROLEMIA WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
    Tada, Hayato
    Kawashiri, Masa-Aki
    Nohara, Atsushi
    Inazu, Akihiro
    Mabuchi, Hiroshi
    Yamagishi, Masakazu
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 1896 - 1896
  • [7] Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
    Tomlinson, Brian
    Patil, Nivritti Gajanan
    Fok, Manson
    Lam, Christopher Wai Kei
    ENDOCRINOLOGY AND METABOLISM, 2021, 36 (02) : 279 - 295
  • [8] PCSK9 inhibition, a potential target to reduce cardiovascular events in patients with familial hypercholesterolemia
    Marques, Patrice
    Domingo, Elena
    Rubio, Arantxa
    Martinez-Hervas, Sergio
    Piqueras, Laura
    Tomas Real, Jose
    Francisco Ascaso, Juan
    Jesus Sanz, Maria
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 125 : 35 - 35
  • [9] NEW GAIN OF FUNCTIONS MUTATIONS IN PCSK9 AND THEIR IMPACT IN FAMILIAL HYPERCHOLESTEROLEMIA
    AbiFadel, M.
    Rabes, J. -P.
    Guerin, M.
    Carreau, V.
    Carrie, A.
    Varret, M.
    Samson-Bouma, M. -E.
    Tosolini, L.
    Erlich, D.
    Couvert, P.
    Bonnefont-Rousselot, D.
    Bruckert, E.
    Prat, A.
    Seidah, N.
    Boileau, C.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 10 - 10
  • [10] PCSK9 gene analysis in Portuguese patients with familial hypercholesterolemia
    Alves, A. C.
    Rato, Q.
    Furtado, A.
    Bourbon, M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2007, 8 (01) : 214 - 215
12345